Literature DB >> 32598958

Enhanced nose-to-brain delivery of tranilast using liquid crystal formulations.

Gerard Lee See1, Florencio Arce1, Sabrina Dahlizar2, Akie Okada3, Muhammad Fikri Bin Mohd Fadli4, Ichiro Hijikuro5, Shoko Itakura6, Masanori Katakura6, Hiroaki Todo6, Kenji Sugibayashi7.   

Abstract

Intranasal administration is poised as a competent method in delivering drugs to the brain, because the nasal route has a direct link with the central nervous system bypassing the formidable blood-brain barrier. C17-monoglycerol ester (MGE) and glyceryl monooleate (GMO) as liquid crystal (LC)-forming lipids possess desirable formulation characteristics as drug carriers for intranasally administered drugs. This study investigated the effect of LC formulations on the pharmacokinetics of tranilast (TL), a lipophilic model drug, and its distribution in the therapeutic target regions of the brain in rats. The anatomical biodistribution of LC formulations was monitored using micro-computed tomography tandem in vivo imaging systems. MGE and GMO effectively formed LC with suitable particle size, zeta potential, and viscosity supporting the delivery of TL to the brain. MGE and GMO LC formulations enhanced brain uptake by 10- to 12-fold and 2- to 2.4- fold, respectively, compared with TL solution. The olfactory bulb had the highest TL concentration and fluorescent signals among all the brain regions, indicating a direct nose-to-brain delivery pathway of LC formulations. LC-forming lipids, MGE and GMO, are potential biomaterials in formulations intended for intranasal administration.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C-17 monoglycerol ester; In vivo imaging; Intranasal drug delivery; Liquid crystals; Micro-computed tomography; Tranilast

Mesh:

Substances:

Year:  2020        PMID: 32598958     DOI: 10.1016/j.jconrel.2020.06.028

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  2 in total

1.  A Lipid-Based Depot Formulation with a Novel Non-lamellar Liquid Crystal Forming Lipid.

Authors:  Akie Okada; Hiroaki Todo; Shoko Itakura; Ichiro Hijikuro; Kenji Sugibayashi
Journal:  Pharm Res       Date:  2021-02-26       Impact factor: 4.580

2.  Development of Self-Administered Formulation to Improve the Bioavailability of Leuprorelin Acetate.

Authors:  Akie Okada; Rina Niki; Yutaka Inoue; Junki Tomita; Hiroaki Todo; Shoko Itakura; Kenji Sugibayashi
Journal:  Pharmaceutics       Date:  2022-04-03       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.